Limerick BioPharma raises $1.5M to limit drug side effects
Limerick BioPharma, a South San Francisco firm specializing in drugs that curb the side effects of other drugs, has brought in $1.5 million in debt, rights and securities that it plans to use as working capital, according to VentureWire. Formerly called Limerick Neurosciences, the company says its products minimize the toxic impact some drugs can have on organs that they aren’t targeting — making more medications safer for a wider range of people. So far, their compounds work to enhance the performance of immunosuppressants, opioids, immunomodulators and others, it says.
Limerick previously raised $20.5 million from Altitude Life Science Ventures, ARCH Venture Partners and Sevin Rosen Funds among others.
Next Story: Motally to deliver reliable mobile analytics
Previous Story: Google Apps syncs with Outlook — a cure for cloud computing angst
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.